Letrozole in the Treatment of Advanced Breast Cancer
Advanced metastatic breast cancer is commonly considered as an incurable disease. In spite of the high rate of objective remissions achieved with the most recent polychemotherapy regimens or hormonal manipulations, the duration of response is limited, the disease progresses and, after a median interval of 24–36 months from the appearance of clinically detectable metastases, the patients inexorably die from cancer. Currently, there are two broad categories of treatment for metastatic breast cancer: cytotoxic chemotherapy and hormonal treatment. Women who are known to have a hormone-dependent tumor usually receive hormonal therapies, as these are better tolerated than chemotherapy.
KeywordsBreast Cancer Clin Oncol Metastatic Breast Cancer Aromatase Inhibitor Advanced Breast Cancer
Unable to display preview. Download preview PDF.
- The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2002). Anastrozole alone or in combination with tamoxifen vs. tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131–2139.CrossRefGoogle Scholar
- Early Breast Cancer Trialists Collaborative Group (1992). Systemic treatment of earlyGoogle Scholar
- breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrencies and 24,000 deaths among 75,000 women. Lancet, 339, 1–15Google Scholar
- Merlano M.C. (2002). Maintenace therapy with letrozole after first-line chemotherapy in advanced breast cancer: the MANTLE trial. 38th ASCO, Orlando (FL), May 18–21, Abstract 1996, 46b.Google Scholar
- Rose C. (2002). Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. 38th ASCO, Orlando (FL), May 18–21, Abstract 131, 34a.Google Scholar
- Thomas R. (2002). Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference. A comparison of letrozole and anastrozole in a multicentre randomised, single-blind cross over study. EBCC, Barcelona, Spain, March 2002, 200, Abstract 171.Google Scholar
- Yamauchi H., Stearns V. and Hayes D.P.(2001): When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19, 2234–2356.Google Scholar